GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Cash, Cash Equivalents, Marketable Securities

Biovica International AB (OSTO:BIOVIC B) Cash, Cash Equivalents, Marketable Securities : kr65.21 Mil (As of Jul. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Cash, Cash Equivalents, Marketable Securities?

Biovica International AB's quarterly cash, cash equivalents, marketable securities declined from Jan. 2024 (kr105.24 Mil) to Apr. 2024 (kr79.41 Mil) but then stayed the same from Apr. 2024 (kr79.41 Mil) to Jul. 2024 (kr65.21 Mil).

Biovica International AB's annual cash, cash equivalents, marketable securities increased from Apr. 2022 (kr89.79 Mil) to Apr. 2023 (kr114.33 Mil) but then declined from Apr. 2023 (kr114.33 Mil) to Apr. 2024 (kr79.41 Mil).


Biovica International AB Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Biovica International AB's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB Cash, Cash Equivalents, Marketable Securities Chart

Biovica International AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.78 145.36 89.79 114.33 79.41

Biovica International AB Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.70 46.93 105.24 79.41 65.21

Biovica International AB Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Biovica International AB  (OSTO:BIOVIC B) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Biovica International AB Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Biovica International AB's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biovica International AB Business Description

Industry
Traded in Other Exchanges
Address
Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB Headlines

No Headlines